Clinical Trial

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Study acronym: NEO-ITHRAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07396324
Lead Sponsor RenJi Hospital
Conditions HR-positive/HER2-negative Breast Cancer
Enrollment 55 participants
Start Date 2026-05-01
Primary Completion 2026-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13